A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Almac Discovery has selected ALM301, a subtype selective Akt1 and Akt2 inhibitor, for its allosteric Akt inhibitor program. Read More
Radius Health and 3M Drug Delivery Systems have formed an exclusive agreement for the development and commercialization for the transdermal delivery of BA058, a synthetic proprietary peptide analog of human parathyroid hormone-related protein for treating osteoporosis. Read More
WuXi PharmaTech and PRA have formed a joint venture to offer clinical-research services for the Chinese market. Read More